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Aims Endothelial dysfunction, platelet hyperactivity, and inflammation play a crucial role in atherogen-
esis. A growing body of evidence suggests that inhibition of the thromboxane A2 (TxA2 or TP) receptor
may improve endothelial function and reduce the inflammatory component of atherosclerosis in
addition to its demonstrated antiplatelet activity. Consequently, we sought to assess the effect of a
novel TP receptor antagonist S18886, on atherosclerotic lesion progression and composition by serial
non-invasive magnetic resonance imaging (MRI).
Methods and results S18886 was compared with control in an experimental model of established aortic
atherosclerosis in New Zealand White rabbits (n ¼ 10). The animals underwent MRI of the abdominal
aorta at the time of randomization and at the end of treatment. Subsequently, animals were euthanized
and specimens were stained for histopathology and immunohistochemistry with anti-a-actin antibodies
for vascular smooth muscle cells (VSMC), anti-RAM-11 for macrophages, anti-caspase-3 for apoptotic
cells, anti-MMP-1 for metalloproteinases, and anti-endothelin-1 (ET-1) as a marker of endothelial dys-
function. MRI analysis revealed a significant reduction in total vessel area (TVA) and vessel wall area
(VWA) in the S18886 group (P, 0.05). Immunostaining analysis showed a significant decrease in RAM-
11, caspase-3, MMP-1, ET-1 and an increase in a-actin in the treated group (P, 0.05 vs. control).
Conclusion Inhibition of the TP receptor by S18886 causes a regression of advanced atherosclerotic
plaques. In addition, the reduction in the markers for macrophages, apoptotic cells, metalloprotei-
nases, and endothelin-1 and the increase in VSMC, suggests that S18886 may not only halt the pro-
gression of atherosclerosis, but also transform lesions towards a more stable phenotype. The
possibility of combining antithrombotic and antiatherosclerotic activity by means of the administration
of TP inhibitors deserves further investigation in a clinical setting.
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Introduction
Endothelial dysfunction, platelet hyperactivity, and inflam-
mation play a crucial role in atherogenesis. A growing
body of evidence suggests that inhibition of the thrombox-
ane A2 (TxA2 or TP) receptor may improve endothelial func-
tion and reduce the inflammatory component of
atherosclerosis in addition to its demonstrated antiplatelet
activity.1 The TP receptors are not only stimulated by
TxA2 but also by virtually all eicosanoids such as the isopros-
tanes. They are capable of inducing platelet aggregation,
vasocontriction, stimulating the expression of adhesion mol-
ecules in endothelial cells, thus leading to leukocyte adher-
ence, inducing apoptosis, and accelerating progression of
atherosclerotic lesions.2,3
The role of platelet activation in atherogenesis has been
extensively investigated.4–9 Originally thought to be simple,
anucleated particles strictly related to the hemostatic
system, activated platelets (through the release of the
content of their a-granules) are now increasingly appreci-
ated as a major source of pro-inflammatory mediators.10
Activated platelets are present in the circulating blood of
atherosclerotic patients.11 They are prone to bind leuko-
cytes, preferentially monocytes, to form platelet–leukocyte
aggregates.12 They may affect endothelial inflammation and
leukocyte–endothelial interactions, which are crucial events
in the pathogenesis of atherosclerosis.5 Our group has
recently reported on the antithrombotic effect of a specific
TP receptor inhibitor (S18886).13 Therefore, an effective and
maintained platelet inhibition may have, in addition to the
antithrombotic effect, a significant impact on the natural
history of atherosclerotic plaques.
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Emerging evidence suggests that selective inhibition of TP
receptors has antiatherosclerotic effects by improving endo-
thelial dysfunction, reducing levels of soluble inflammatory
markers (e.g. ICAM-1), preventing macrophage accumu-
lation, and inhibiting platelet activation andaggregation.14,15
Specifically, Cayatte et al.14 reported a reduction in the
development of atherosclerosis in apoE deficient mice after
11weeks of treatmentwith the selective TPreceptor inhibitor
S18886. Furthermore, a recent study, using atherosclerosis-
prone (apoE2/2) and TP receptor deficient (TP2/2) mice,
showed that these animals had less platelet reactivity, endo-
thelial dysfunction, leukocyte–endothelial cell interaction,
and importantly a reduction of 30% in atherosclerotic
plaque formation.1 Consequently, and based on the available
evidence, we decided to evaluate the potential anti-
atherosclerotic activity of S18886, a novel, orally active,
specific TP receptor antagonist in an experimental model of
established atherosclerosis characterized by advanced,
complex atherosclerotic lesions.
Methods
Experimental model of atherosclerosis
Advanced aortic atherosclerotic lesions were induced in male New
Zealand white rabbits (n ¼ 10, age ¼ 3 months, weight ¼
3.5+ 0.2 kg, Covance, Princeton, NJ, USA) by a combination of 9
months of high-cholesterol (HC) diet and double aortic balloon
denudation injury (at months 1 and 3) as previously described.16–18
All procedures were performed under general anaesthesia by intra-
muscular ketamine injection (20 mg/kg, Fort Dodge Animal Health,
Fort Dodge, IA, USA) and xylazine (10 mg/kg, Bayer Corporation,
Shawnee Mission, KA, USA). The study protocol was approved by
the Internal Review Board of Mount Sinai School of Medicine.
Study design
After 9 months of atherosclerosis induction, the animals were ran-
domized to either S18886 (5 mg/kg/day) plus HC diet, or HC
diet alone. The treatment period was 6 months. The experimental
model of atherosclerosis utilized in this study has already demon-
strated consistency on the development of advanced atherosclero-
tic lesions.19
Magnetic resonance imaging
Nine months after initiation of the atherogenic diet, all rabbits
underwent in vivo magnetic resonance imaging (MRI) study (‘ather-
osclerosis control’). The animals were anaesthetized and placed
supine in a 1.5 T clinical MRI system (Sigma, General Electric)
using a conventional phased-array volume coil.19 Gradient echo
coronal images were used to localize the abdominal aorta.
Thereafter, sequential axial images (3 mm thickness) of the aorta
from the right renal artery to the iliac bifurcation were obtained
using a fast spin-echo sequence (total imaging time 45 min) with
an in-plane resolution of 300  300 mm [proton density weighted
(PDW):TR/TE, 2.300/17 ms; T2W:TR/TE, 2.300/60 ms, T1W:TR/
TE, 800/5.6 ms, field of view ¼ 9  9 cm, matrix 256  256, echo
train length ¼ 8, signal averages ¼ 4].16 The procedure was
repeated at the end of the treatment period prior to sacrifice
(‘end of treatment’).
Histopathology and immunohistochemistry
At the end of the study, animals were euthanized within 48 h of the
MRI by intravenous injection of Sleepaway 5 mL i.v. (Fort Dodge
Animal Health) after receiving heparin (100 U/kg) to prevent post-
mortem blood clotting. The aorta was removed and fixed in
paraformaldhehyde (4% in phosphate-buffered saline), serial sec-
tions of the aorta were cut at 3 mm intervals matching correspond-
ing MR images. The selected aortic specimens were paraffin-
embedded, and 5 mm thick sections were cut and stained with com-
bined Masson’s trichome elastin stain. Macrophage detection was
performed by immunohistochemistry with the RAM-11 antibody.
Anti-a-actin antibodies was used for vascular smooth muscle cells
(VSMC), anti-caspase-3 for apoptotic cells, anti-MMP-1 for metallo-
proteinases, and anti-endothelin-1 (ET-1) as a marker of endothelial
dysfunction. Dilutions were determined using controls at the time of
staining.
Image analysis
The MR images were transferred to a Macintosh computer for
further analysis. Cross-sectional areas of the lumen and outer
boundary of each section were determined by manual tracing with
Image Pro-Plus (Media Cybernetics). From these measurements,
mean wall thickness (MWT), vessel wall area (VWA), total vessel
area (TVA), and lumen area (LA) were calculated (Figure 1 ). Two
experienced investigators blindly and randomly analysed each of
the MRI and histopathology sections (n ¼ 327). In order to match
the slices in the both modalities (MRI and Histopathology), the
right renal artery was taken as an anatomic reference. The slices
for each rabbit were numbered cranio-caudally, the first slice
being the one containing the right renal artery and the last
section the one containing the bifurcation into the iliac arteries.
Histopathology and immunostaining analysis (RAM-11, MMP-1,
caspase-3, endothelin-1, and a-actin) were quantified by compu-
ter-assisted planimetry with Image Pro-Plus (Media Cybernetics).
Statistical analysis
After we tested for normal distribution and equality of variances
with Levene’s F test, the effectiveness of the treatment was ana-
lysed with unpaired t-tests by comparing S18886 and placebo
groups. Paired t-test was used to compare the MR image-derived
parameters within groups at the two time points. All probabilities
are two-sided, with statistical significance taken as a value of
P , 0.05. All values are expressed as mean+ SD.
Results
Magnetic resonance imaging
When comparing ‘atherosclerosis control’ vs. ‘end of treat-
ment’ studies within groups, there was observed a mean
reduction in TVA of 12.6+ 9.8% (from 21.9+ 7.5 to
18.7+ 5 mm2; P, 0.05) (mean+ SD) in the S18886 group,
whereas in the control group there was a slight increase of
3.6+ 8.1% (from 19.3+ 7.4 to 19.9+ 7.8 mm2; P ¼ 0.11).
The LA increased from 6.97+ 2.1 to 6.98+ 1.4 mm2
(P ¼ 0.97) in the S18886 group and 1.7+ 23.8% (from
6.1+ 4.1 to 6.3+ 4.6 mm2; P ¼ 0.95) in the control
group. The VWA (plaque burden) was reduced by
Figure 1 Scheme illustrating the parameters assessed by MRI and histo-
pathology. VWA, vessel wall area; LA, lumen area; TVA, total vessel area.
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18.5+ 15.3% (from 14.6+ 6.1 to 11.7+ 4.6 mm2;
P, 0.05) in the group receiving the study drug, and
increased 5.7+ 9.6% (from 13.0+ 4.1 to 13.64+ 3.8 mm2;
P ¼ 0.06) in the control group (Table 1 ). When the
changes in VWA and TVA were compared among groups,
there was a statistically significant difference (P, 0.001).
The comparison of changes in LA among groups was not stat-
istically significant. Interestingly, the qualitative analysis of
plaque composition with multicontrast MRI revealed that
overall the atherosclerotic lesions of the S18886 group pre-
sented lower content of lipids [low signal intensity (SI) in
T2W, high SI in T1W] and higher content of fibrotic material
(high SI in T2W and T1W) than the control group (Figures 2
and 3 ).
Histopathology
The histopathology analysis showed that the mean
difference between groups for TVA was 4.4+ 0.36 mm2.
For VWA, LA, and MWT, the mean difference was
3.35+ 0.43, 1.05+ 0.21, and 0.13+ 0.011 mm2, respec-
tively. In line with the MRI findings, the histopathology
demonstrated more fibrous rich plaques in the treatment
group than in the control group and more lipid rich
plaques in the control group than in the group receiving
the study drug.
Immunohistochemistry
The RAM-11 staining revealed that the content of macro-
phages in the atherosclerotic plaques of the treatment
group was lower than in the control group. The mean area
of macrophages, expressed as a percentage of the TVA, was
1.1+ 1.3 and 6.6+ 5.2% (P, 0.05), respectively. Equally,
the occurrence of apoptotic cells (caspase-3) was lower in
the treatment group (9.3+ 4.3%) than in the control
(19.7+ 6.4%; P, 0.05). In accordance with the MRI data,
the presence of a-actin-positive areas (reflecting areas rich
in VSMC) was higher in the treatment group (8.7+ 6.9%)
than in the control group (1.6+ 1.5%; P , 0.05), giving a
mean difference among groups of 7.0%. The immunostaining
for MMP-1 showed more positive areas in the control group
(11.5+ 6.7%) than in the group receiving S18886
(3.2+ 2.8%; P, 0.05), allowing for a difference of 8.3%.
Endothelin-1-positive areaswere 2.9+ 4.1% in the treatment
group and 6.2+ 6.8% (P, 0.05) in the control group
(Figure 4 ).
Discussion
We are reporting, for the first time, regression of already
established atherosclerosic lesions after 6 months of treat-
ment with a selective TP receptor inhibitor in a rabbit
model of atherosclerosis while maintaining the atherogenic
diet. Our results showed a reduction in plaque burden
(VWA) and TVA as assessed by MRI. In addition, MRI showed
a slight increase in the LA of the group receiving S18886.
Importantly, there was a change in the phenotype of the
atherosclerotic plaques in the treatment group. The
reduction in the content of macrophages, apoptotic cells,
MMP-1- and endothelin-1-positive areas, and the increase in
a-actin-positive areas, suggests that selective inhibition of
TxA2 pathway may confer a more stable plaque phenotype.
TxA2 is the major COX-1 (cyclooxygenase) product of ara-
chidonic acid metabolism in platelets. Its biosynthesis is also
incremented in the smooth muscle cells and macrophages of
patients with atherosclerosis.20,21 TxA2 is considered to be
one of the most powerful agonists for platelet activation
and thus, thrombus formation. In addition, TxA2 exerts a
vasoconstrictor effect by serving as an agonist of theTPrecep-
tors on the vascular smoothmuscle cellmembranes. The criti-
cal effect of TxA2 on platelet activation and thrombosis has
been clearly demonstrated by the clinical effectiveness of
acetylsalicylic acid (ASA) in the prevention of acute coronary
syndromes.22 ASA irreversibly inactivates the enzyme
cyclooxygenase COX-1 via its acetylation. The inhibition of
this enzymenot only inhibits the synthesis of TxA2byplatelets
but, at high concentrations, itmay also inhibit the endothelial
cyclooxygenase COX-2.23 Selective inhibition of COX-2 has
been recently associated with an increased risk of CAD and
has resulted in the removal of one of this agents from the
market.24 TxA2 is mainly synthesized by the COX-1 enzyme
in the platelets, whereas prostacyclin (PGI2) is synthesized
by the COX-2 isoform.2,23 Therefore, the availability of
a selective blockade of TxA2, by blocking either
its synthesis or its receptors without affecting the synthesis
of PGI2, could have significant clinical implications
by redirecting the arachidonic cascade towards the pro-
duction of inhibitory and vasodilator prostanoids (PGI2 and
prostaglandin D).3
S18886 is an orally active, specific, potent blocker of the
receptor for TxA2 and related compounds (endoperoxides
and isoprostanes), which does not affect the synthesis of
PGI2. Its synthesis and biological evaluation have already
been reported.26 It is intended for use in the prevention of
Table 1 Assessment of atherosclerosis burden by MRI and ather-
osclerotic plaque composition by immunohistochemistry
S18886 Control
MRI
Change in TVA (%) 212.6+ 9.8a 3.6+ 8.12
Change in LA (%) 5.7+ 25.5 21.7+ 23.84
Change in VWA (%) 218.5+ 15.3a 5.7+ 9.7
Immunohistochemistry
RAM-11 1.1+ 1.3a 6.6+ 5.2
Caspase-3 9.3+ 4.3a 19.7+ 6.4
MMP-1 3.2+ 2.8a 11.5+ 6.7
Endothelin-1 2.9+ 4.1a 6.2+ 6.8
a-Actin 8.7+ 6.9a 1.6+ 1.5
All values are expressed as mean+ SD. Units in the immunostaining are
% of TVA.
aP , 0.05.
Figure 2 Representative cross sectional MR images of the abdominal aorta
showing regression in the S18886 group. The panel on the left shows a
section obtained at the time of randomization (baseline) showing a rim of
low SI (white arrowheads) and right panel shows the same image at the end
of treatment. Asterisk indicates lumen of abdominal aorta.
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thrombotic events in patients with cardiovascular diseases.
The antiplatelet activity of S18886 has been previously
demonstrated by our group13 and the compound is now in
phase III of clinical development. Interestingly, experimen-
tal and clinical evidence indicate that the compound has
some antiatherosclerotic properties also.14,15 Similarly,
another TxA2 inhibitor has also shown favourable effects
on atherosclerotic vessels.27,28 More recently, a combined
inhibitor of TxA2 synthase and receptor reduced 2 year
overall mortality in diabetic patients with peripheral arter-
ial disease.29
The potential mechanism of action for the observed
effects of the S18886 may include a ‘pleiotropic’ anti-
inflammatory effect (due to the reduction in the number
of macrophages) which in turn abrogates the apoptotic
phenomenon, rendering a beneficial effect on the endo-
thelium15 (due to the reduction in the endothelin-1-positive
areas), and a mitogenic effect on VSMC, all of which are
crucial to the progression of atherosclerosis. Indeed, two
independent groups have formerly demonstrated the
impact of inhibiting the thromboxane pathway in atherogen-
esis; Cayatte et al.14 reported a reduction in the develop-
ment of atherosclerosis in apoE deficient mice after 11
weeks of treatment with the selective TP receptor
inhibitor S18886. Furthermore, a recent study using athero-
sclerosis-prone (apoE2/2) and TP receptor deficient
(TP2/2) mice showed that these animals had less platelet
reactivity, endothelial dysfunction, leukocyte–endothelial
cell interaction, and importantly a reduction of 30% in
atherosclerotic plaque formation.1
Compelling evidence on the importance of endothelial
dysfunction, platelet activation, and inflammation in
the genesis of atherosclerosis has been accumulated over
the last decades. Activated platelets may provide the reac-
tive surface for the recruitment of monocytes and lympho-
cytes by releasing the content of their granules, increasing
the expression of adhesive ligands (such as P-selectin), or
binding molecules from the plasma milieu (such as fibrino-
gen). These interactions may support the adhesion of leuko-
cytes to the vessel wall even in conditions of high flow that
would otherwise not permit this. Platelets also release
growth factors (platelet-derived growth factor), proinflam-
matory cytokines (such as CD40 ligand and IL-1), and chemo-
kines (such as RANTES and platelet factor-4).6 Recent data
emphasize the possible influence of platelets on the cellular
metabolism of lipoproteins, indicating a more direct invol-
vement in the early changes characteristic of the athero-
sclerotic lesion.30,31 All these processes favour the
recruitment of monocytes to the vessel wall, which even-
tually undergo apoptosis32 and perpetuate the inflammatory
Figure 4 Representative histologic sections of the treatment (upper row) and control (lower row) groups. (A ) and (B ) are a-Actin (VSMC) showing more staining
in the treated group; (C ) and (D ) RAM-11 (macrophages); (E ) and (F ) MMP-1 (metalloproteinases); (G) and (H) endothelin-1; (I ) and (J ) caspase-3 (apoptosis).
(C )–(J ) are evidencing more staining positive areas in the control group.
Figure 3 Graphical representation of MRI changes.
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milieu within the atheromatous plaque. In addition, the
interaction of activated platelets and their secreted pro-
ducts with endothelial cells is postulated as a trigger of
the endothelial dysfunction and inflammation. It is now
accepted that the higher the content of pro-inflammatory
elements, such as macrophages and metalloproteases, the
higher the risk of plaque disruption.
Our study is the first one reporting effect of regression of
established atherosclerotic lesions. A major advantage of
this study is that it demonstrates ‘real’ atherosclerosis
regression given that by using serial MRI each animal
serves as its own control. A limitation of the present study
is that it does not provide a precise mechanistic explanation
for the antiatherosclerotic effect of selective TP receptor
inhibition. Hence, there are several questions that remain
unanswered. Could the observed regression of atherosclero-
sis be extrapolated to other antiplatelet interventions as
recently suggested33 or is the antiatherosclerotic effect con-
ferred by this agent explained solely by its TP receptor inhi-
bition activity? In spite of the limitations, we believe this
study opens new paths of investigation in the pathogenesis
of atherosclerosis and may eventually modify the manner
in which we understand the beneficial effect of ‘antithrom-
botic’ therapy.
In conclusion, based on the results of MRI, histopathology,
and immunohistochemistry analysis, it can be concluded
that the compound S18886 might have a potential antiather-
osclerotic and plaque stabilizing effect. The possibility of
combining antiplatelet activity (without inhibiting the syn-
thesis of PGI2) with an antiatherosclerotic effect through
the administration of TP inhibitors could have very import-
ant clinical implications, and therefore deserves further
investigation in a clinical setting.
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